Why the study?
A declining prevalence of abdominal aortic aneurysm might force a targeted screening approach in high-risk populations to maintain cost-effectiveness.
What is the prevalence and prognostic impact of screening-detected abdominal aortic aneurysm in patients with clinically manifest vascular disease?
What is the prevalence and prognostic impact of screening-detected abdominal aortic aneurysm in patients with clinically manifest vascular disease?
Although the prevalence of screening-detected AAA in patients with vascular disease has declined over time, it remains higher than in established screening programs for 65-year-old men and is associated with significantly lower long-term survival.
Answers are grounded in this paper and cite their sources.
May identify higher-risk vascular disease subgroups; leaves open whether targeted AAA screening improves outcomes.
AIMS: Declining prevalence of abdominal aortic aneurysm (AAA) might force a more targeted screening approach (high-risk populations only) in order to maintain (cost-)effectiveness. We aimed to determine temporal changes in the prevalence of screening-detected AAA, to assess AAA-related surgery, and evaluate all-cause mortality in patients with manifest vascular disease. METHODS AND RESULTS: We included patients with manifest vascular disease but without a history of AAA enrolled in the ongoing single-centre prospective UCC-SMART cohort study. Patients were screened at baseline for AAA by abdominal ultrasonography. We calculated sex- and age-specific prevalence of AAA, probability of survival in relation to the presence of AAA, and the proportion of patients undergoing AAA-related surgery. Prevalence of screening-detected AAA in 5440 screened men was 2.5% [95% confidence interval (CI) 2.1-2.9%] and in 1983 screened women 0.7% (95% CI 0.4-1.1%). Prevalence declined from 1997 until 2017 in men aged 70-79 years from 8.1% to 3.2% and in men aged 60-69 years from 5.7% to 1.0%. 36% of patients with screening-detected AAA received elective AAA-related surgery during follow-up (median time until surgery = 5.3 years, interquartile range 2.5-9.1). Patients with screening-detected AAA had a lower probability of survival (sex and age adjusted) compared to patients without screening-detected AAA (51%, 95% CI 41-64% vs. 69%, 95% CI 68-71%) after 15 years of follow-up. CONCLUSION: The prevalence of screening-detected AAA has declined over the period 1997-2017 in men with vascular disease but exceeds prevalence in already established screening programs targeting 65-year-old men. Screening for AAA in patients with vascular disease may be cost-effective, but this remains to be determined.
No takes yet. Share an insight, caveat, or question.
Boer et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: